Becton Dickinson
About: Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.
Employees: 74,000
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
82% more funds holding in top 10
Funds holding in top 10: 11 [Q3] → 20 (+9) [Q4]
45% more first-time investments, than exits
New positions opened: 177 | Existing positions closed: 122
16% more call options, than puts
Call options by funds: $320M | Put options by funds: $275M
0.74% more ownership
Funds ownership: 88.7% [Q3] → 89.44% (+0.74%) [Q4]
1% less funds holding
Funds holding: 1,546 [Q3] → 1,537 (-9) [Q4]
3% less capital invested
Capital invested by funds: $62B [Q3] → $60.1B (-$1.84B) [Q4]
16% less repeat investments, than reductions
Existing positions increased: 519 | Existing positions reduced: 621
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$279
23%
upside
Avg. target
$280
23%
upside
High target
$280
23%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Barclays Travis Steed 0% 1-year accuracy 0 / 4 met price target | 23%upside $279 | Overweight Maintained | 14 Feb 2025 |
Piper Sandler Jason Bednar 45% 1-year accuracy 17 / 38 met price target | 23%upside $280 | Overweight Maintained | 28 Jan 2025 |
Financial journalist opinion
Based on 19 articles about BDX published over the past 30 days
Neutral
PRNewsWire
1 week ago
BD to Present at Investor Healthcare Conferences
FRANKLIN LAKES, N.J. , Feb. 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following healthcare conferences: Citi's 2025 Unplugged Medtech and Life Sciences Access Day February 27, 2025 8:45 a.m.
Positive
Zacks Investment Research
1 week ago
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Positive
CNBC
2 weeks ago
Starboard pushes an open door at Becton Dickinson as company seeks to separate its biosciences unit
Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The company aims to do just that.
Neutral
Seeking Alpha
2 weeks ago
Becton, Dickinson and Company (BDX) Q1 2025 Earnings Call Transcript
Becton, Dickinson and Company (BDX) Q1 2025 Earnings Call Transcript
Neutral
Benzinga
2 weeks ago
Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business
On Wednesday, Becton, Dickinson and Company BDX authorized to pursue a plan to separate BD's Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus, and growth-oriented investments and capital allocation.
Neutral
Zacks Investment Research
2 weeks ago
Compared to Estimates, Becton Dickinson (BDX) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Becton Dickinson (BDX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Positive
Zacks Investment Research
2 weeks ago
Becton Dickinson (BDX) Tops Q1 Earnings and Revenue Estimates
Becton Dickinson (BDX) came out with quarterly earnings of $3.43 per share, beating the Zacks Consensus Estimate of $2.98 per share. This compares to earnings of $2.68 per share a year ago.
Neutral
Reuters
2 weeks ago
Becton Dickinson looks to separate life sciences unit
Becton Dickinson said on Wednesday its board has authorized a plan to separate its life sciences unit as the medical device maker aims to focus on its core business.
Neutral
PRNewsWire
2 weeks ago
BD Announces Intent to Separate Biosciences and Diagnostic Solutions Business to Enhance Focus, Drive Growth and Unlock Value
Compelling opportunity expected to unlock substantial value through enhanced focus, tailored investment and capital allocation, and optimized market valuation "New BD," built on momentum of BD 2025 strategy, will be well-positioned as a scaled, pure-play MedTech leader focused on attractive categories shaping the future of health care Biosciences and Diagnostic Solutions to realize its full market potential as differentiated leader in Life Sciences Tools and Diagnostics, with robust innovation pipeline and headroom for growth in key sectors FRANKLIN LAKES, N.J. , Feb. 5, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD's Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus and growth-oriented investments and capital allocation for both BD and the separated business and enhance value creation for shareholders.
Neutral
PRNewsWire
2 weeks ago
BD Reports First Quarter Fiscal 2025 Financial Results
Company Delivers Revenue, Margin and Earnings Ahead of its Expectations Revenue of $5.2 billion increased 9.8% as reported, 9.6% currency-neutral and 3.9% organic GAAP and adjusted diluted EPS of $1.04 and $3.43 grew 8.3% and 28.0%, respectively BD completes $750 million share repurchase to date in FY25 Company increases FY25 adjusted diluted EPS guidance at the midpoint while absorbing translational currency1 FRANKLIN LAKES, N.J. , Feb. 5, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 first quarter which ended December 31, 2024.
Charts implemented using Lightweight Charts™